{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T03:25:42Z","timestamp":1763695542539,"version":"3.45.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008376","name":"Helsingin ja Uudenmaan Sairaanhoitopiiri","doi-asserted-by":"publisher","award":["TYH2019309","TYH2023319"],"award-info":[{"award-number":["TYH2019309","TYH2023319"]}],"id":[{"id":"10.13039\/100008376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005633","name":"Syd\u00e4ntutkimuss\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010133","name":"Aarne Koskelon S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010133","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010114","name":"Yrj\u00f6 Jahnssonin S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010114","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40801-025-00519-5","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T18:11:16Z","timestamp":1759860676000},"page":"631-641","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost Differences Between Oral Anticoagulation Therapies in Patients with Atrial Fibrillation in Finland"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4914-1027","authenticated-orcid":false,"given":"Ossi","family":"Lehtonen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9266-8435","authenticated-orcid":false,"given":"Olli","family":"Halminen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0193-568X","authenticated-orcid":false,"given":"K. E. Juhani","family":"Airaksinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1450-6208","authenticated-orcid":false,"given":"Jari","family":"Haukka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6630-6104","authenticated-orcid":false,"given":"Jukka","family":"Putaala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1319-0248","authenticated-orcid":false,"given":"Pirjo","family":"Mustonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4460-0994","authenticated-orcid":false,"given":"Konsta","family":"Teppo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5759-0916","authenticated-orcid":false,"given":"Elis","family":"Kouki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7030-6740","authenticated-orcid":false,"given":"Aapo L.","family":"Aro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0847-107X","authenticated-orcid":false,"given":"Juha","family":"Hartikainen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8691-5142","authenticated-orcid":false,"given":"Mika","family":"Lehto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7660-2484","authenticated-orcid":false,"given":"Miika","family":"Linna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"issue":"1","key":"519_CR1","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10654-021-00812-x","volume":"37","author":"M Lehto","year":"2022","unstructured":"Lehto M, Halminen O, Mustonen P, Putaala J, Linna M, Kinnunen J, et al. The nationwide Finnish anticoagulation in atrial fibrillation (FinACAF): study rationale, design, and patient characteristics. Eur J Epidemiol. 2022;37(1):95\u2013102.","journal-title":"Eur J Epidemiol"},{"issue":"2","key":"519_CR2","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/ehjqcco\/qcaa093","volume":"8","author":"P Burdett","year":"2020","unstructured":"Burdett P, Lip GYH. Atrial fibrillation in the UK: predicting costs of an emerging epidemic recognizing and forecasting the cost drivers of atrial fibrillation-related costs. Eur Heart J Qual Care Clin Outcomes. 2020;8(2):187\u201394.","journal-title":"Eur Heart J Qual Care Clin Outcomes."},{"issue":"1","key":"519_CR3","doi-asserted-by":"publisher","first-page":"2364825","DOI":"10.1080\/07853890.2024.2364825","volume":"56","author":"M Lehto","year":"2024","unstructured":"Lehto M, Luojus A, Halminen O, Haukka J, Putaala J, Linna M, et al. Time-in-therapeutic-range defined warfarin and direct oral anticoagulants in atrial fibrillation: a nationwide cohort study. Ann Med. 2024;56(1):2364825.","journal-title":"Ann Med"},{"issue":"2","key":"519_CR4","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jval.2011.09.009","volume":"15","author":"WP Wodchis","year":"2012","unstructured":"Wodchis WP, Bhatia RS, Leblanc K, Meshkat N, Morra D. A review of the cost of atrial fibrillation. Value Health. 2012;15(2):240\u20138.","journal-title":"Value Health"},{"issue":"11","key":"519_CR5","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s40273-024-01419-2","volume":"42","author":"RJ Mulholland","year":"2024","unstructured":"Mulholland RJ, Ciminata G, Quinn TJ, Pollock KG, Lister S, Geue C. Delay and pay? Healthcare costs associated with late oral anti-coagulant prescribing in people with atrial fibrillation. Pharmacoeconomics. 2024;42(11):1241\u201353.","journal-title":"Pharmacoeconomics"},{"key":"519_CR6","unstructured":"Rissanen A, Herse F, Rossi J, S\u00e4\u00e4vuori N, Roine RO, Pakarinen S. Eteisv\u00e4rin\u00e4\u00e4 sairastavien potilaiden antikoagulaatiohoito ja palveluiden k\u00e4ytt\u00f6 Suomessa. Suomen l\u00e4\u00e4k\u00e4rilehti. 2021."},{"key":"519_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40256-016-0204-1","volume":"17","author":"K Athanasakis","year":"2017","unstructured":"Athanasakis K, Boubouchairopoulou N, Karampli E, Tarantilis F, Savvari P, Bilitou A, et al. Cost effectiveness of apixaban versus warfarin or aspirin for stroke prevention in patients with atrial fibrillation: a Greek perspective. Am J Cardiovasc Drugs. 2017;17:123\u201333.","journal-title":"Am J Cardiovasc Drugs"},{"key":"519_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12913-021-06084-1","volume":"21","author":"H Wei","year":"2021","unstructured":"Wei H, Cui C, Cui X, Liu Y, Li D. Cost-effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China. BMC Health Serv Res. 2021;21:1\u201310.","journal-title":"BMC Health Serv Res"},{"issue":"3","key":"519_CR9","doi-asserted-by":"publisher","first-page":"252","DOI":"10.4070\/kcj.2018.0220","volume":"49","author":"H Kim","year":"2019","unstructured":"Kim H, Kim H, Cho SK, Kim JB, Joung B, Kim C. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Korean Circ J. 2019;49(3):252.","journal-title":"Korean Circ J"},{"key":"519_CR10","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s40273-013-0090-1","volume":"31","author":"C Kasmeridis","year":"2013","unstructured":"Kasmeridis C, Apostolakis S, Ehlers L, Rasmussen LH, Boriani G, Lip GY. Cost effectiveness of treatments for stroke prevention in atrial fibrillation: focus on the novel oral anticoagulants. Pharmacoeconomics. 2013;31:971\u201380.","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"519_CR11","first-page":"179","volume":"34","author":"J Ferreira","year":"2015","unstructured":"Ferreira J, Mirco A. Systematic review of cost-effectiveness analyses of novel oral anticoagulants for stroke prevention in atrial fibrillation. Revista Portuguesa de Cardiologia (Engl Ed). 2015;34(3):179\u201391.","journal-title":"Revista Portuguesa de Cardiologia (Engl Ed)."},{"key":"519_CR12","doi-asserted-by":"crossref","unstructured":"Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): Developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO). Eur Heart J. 2024;45(36):3314\u2013414.","DOI":"10.1093\/eurheartj\/ehae176"},{"issue":"3","key":"519_CR13","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1055\/s-0038-1651587","volume":"69","author":"F Rosendaal","year":"1993","unstructured":"Rosendaal F, Cannegieter S, van der Meer F, Bri\u00ebt E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236\u20139.","journal-title":"Thromb Haemost"},{"key":"519_CR14","unstructured":"M\u00e4klin S, Kokko P. Terveyden-ja sosiaalihuollon yksikk\u00f6kustannukset Suomessa vuonna 2017. 2021;"},{"issue":"5","key":"519_CR15","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","volume":"11","author":"JM Robins","year":"2000","unstructured":"Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11(5):550\u201360.","journal-title":"Epidemiology"},{"issue":"6","key":"519_CR16","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/joim.12197","volume":"275","author":"T St\u00fcrmer","year":"2014","unstructured":"St\u00fcrmer T, Wyss R, Glynn RJ, Brookhart MA. Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs. J Intern Med. 2014;275(6):570\u201380.","journal-title":"J Intern Med"},{"issue":"19","key":"519_CR17","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1002\/sim.5753","volume":"32","author":"DF McCaffrey","year":"2013","unstructured":"McCaffrey DF, Griffin BA, Almirall D, Slaughter ME, Ramchand R, Burgette LF. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med. 2013;32(19):3388\u2013414.","journal-title":"Stat Med"},{"key":"519_CR18","doi-asserted-by":"publisher","first-page":"205031211875944","DOI":"10.1177\/2050312118759444","volume":"6","author":"JA Delaney","year":"2018","unstructured":"Delaney JA, Yin X, Fontes JD, Wallace ER, Skinner A, Wang N, et al. Hospital and clinical care costs associated with atrial fibrillation for Medicare beneficiaries in the Cardiovascular Health Study and the Framingham Heart Study. Sage Open Med. 2018;6:2050312118759444.","journal-title":"Sage Open Med"},{"issue":"9","key":"519_CR19","first-page":"789","volume":"19","author":"J Biskupiak","year":"2013","unstructured":"Biskupiak J, Ghate SR, Jiao T, Brixner D. Cost implications of formulary decisions on oral anticoagulants in nonvalvular atrial fibrillation. J Manag Care Pharm. 2013;19(9):789\u201398.","journal-title":"J Manag Care Pharm"},{"issue":"3","key":"519_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/ehjopen\/oeaf046","volume":"5","author":"A Luojus","year":"2025","unstructured":"Luojus A, Lehto M, Halminen O, Lehtonen O, Niemi M, Teppo K, et al. Reduced dose direct oral anticoagulants and time-in-therapeutic-range defined warfarin in new-onset atrial fibrillation: a report from the nationwide FinACAF study. Eur Heart J Open. 2025;5(3):oeaf046.","journal-title":"Eur Heart J Open"},{"issue":"3","key":"519_CR21","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s12325-015-0189-1","volume":"32","author":"F Lalibert\u00e9","year":"2015","unstructured":"Lalibert\u00e9 F, Cloutier M, Crivera C, Nelson WW, Olson WH, Schein J, et al. Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users. Adv Ther. 2015;32(3):216\u201327.","journal-title":"Adv Ther"},{"issue":"3","key":"519_CR22","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.clinthera.2016.01.008","volume":"38","author":"T Bancroft","year":"2016","unstructured":"Bancroft T, Lim J, Wang C, Sander SD, Swindle JP. Health care resource utilization, costs, and persistence in patients newly diagnosed as having nonvalvular atrial fibrillation and newly treated with dabigatran versus warfarin in the United States. Clin Ther. 2016;38(3):545\u201356.","journal-title":"Clin Ther"},{"issue":"1","key":"519_CR23","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12955-017-0705-x","volume":"15","author":"SL Reynolds","year":"2017","unstructured":"Reynolds SL, Ghate SR, Sheer R, Gandhi PK, Moretz C, Wang C, et al. Healthcare utilization and costs for patients initiating Dabigatran or Warfarin. Health Qual Life Outcomes. 2017;15(1):128.","journal-title":"Health Qual Life Outcomes"},{"issue":"11","key":"519_CR24","first-page":"1191","volume":"23","author":"S Deitelzweig","year":"2017","unstructured":"Deitelzweig S, Luo X, Gupta K, Trocio J, Mardekian J, Curtice T, et al. Effect of apixaban versus warfarin use on health care resource utilization and costs among elderly patients with nonvalvular atrial fibrillation. J Manag Care Spec Pharm. 2017;23(11):1191\u2013201.","journal-title":"J Manag Care Spec Pharm"},{"key":"519_CR25","doi-asserted-by":"crossref","unstructured":"Greenspon AJ. An economic analysis of stroke and atrial fibrillation. In: Flaker G, editor. Stroke prevention in atrial fibrillation. United States: Elsevier; 2018. pp. 1\u201310.","DOI":"10.1016\/B978-0-323-55429-9.00001-7"},{"key":"519_CR26","doi-asserted-by":"publisher","first-page":"745","DOI":"10.2147\/CEOR.S317078","volume":"13","author":"T Hallinen","year":"2021","unstructured":"Hallinen T, Soini E, Asseburg C, Linna M, Eloranta P, Sintonen S, et al. Cost-effectiveness of apixaban versus other direct oral anticoagulants and warfarin in the prevention of thromboembolic complications among Finnish patients with non-valvular atrial fibrillation. Clinicoecon Outcomes Res. 2021;13:745\u201355.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"1","key":"519_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40064-016-3024-5","volume":"5","author":"T Hallinen","year":"2016","unstructured":"Hallinen T, Soini EJ, Linna M, Saarni SI. Cost\u2013effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients. Springerplus. 2016;5(1):1\u20139.","journal-title":"Springerplus"},{"issue":"3","key":"519_CR28","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3111\/13696998.2013.766200","volume":"16","author":"H Wouters","year":"2013","unstructured":"Wouters H, Thijs V, Annemans L. Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium. J Med Econ. 2013;16(3):407\u201314.","journal-title":"J Med Econ"},{"issue":"6","key":"519_CR29","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1161\/CIRCOUTCOMES.113.000661","volume":"6","author":"WJ Canestaro","year":"2013","unstructured":"Canestaro WJ, Patrick AR, Avorn J, Ito K, Matlin OS, Brennan TA, et al. Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2013;6(6):724\u201331.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"1","key":"519_CR30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1185\/03007995.2015.1103217","volume":"32","author":"S Deitelzweig","year":"2016","unstructured":"Deitelzweig S, Evans M, Hillson E, Trocio J, Bruno A, Tan W, et al. Warfarin time in therapeutic range and its impact on healthcare resource utilization and costs among patients with nonvalvular atrial fibrillation. Curr Med Res Opin. 2016;32(1):87\u201394.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"519_CR31","first-page":"457","volume":"114","author":"P Silva","year":"2020","unstructured":"Silva P, Sznejder H, Vasconcellos R, Charles GM, Mendonca-Filho HTF, Mardekian J, et al. Anticoagulation therapy in patients with non-valvular atrial fibrillation in a private setting in Brazil: a real-world study. Arq Bras Cardiol. 2020;114(3):457\u201366.","journal-title":"Arq Bras Cardiol"},{"key":"519_CR32","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s11606-013-2639-2","volume":"29","author":"JH You","year":"2014","unstructured":"You JH. Novel oral anticoagulants versus warfarin therapy at various levels of anticoagulation control in atrial fibrillation\u2014a cost-effectiveness analysis. J Gen Intern Med. 2014;29:438\u201346.","journal-title":"J Gen Intern Med"},{"key":"519_CR33","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s11239-013-1048-z","volume":"38","author":"A Amin","year":"2014","unstructured":"Amin A, Deitelzweig S, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, et al. Estimation of the impact of warfarin\u2019s time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials. J Thromb Thrombolysis. 2014;38:150\u20139.","journal-title":"J Thromb Thrombolysis"},{"key":"519_CR34","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s40273-014-0246-7","volume":"33","author":"A Janzic","year":"2015","unstructured":"Janzic A, Kos M. Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control. Pharmacoeconomics. 2015;33:395\u2013408.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"519_CR35","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.jval.2013.01.009","volume":"16","author":"D Coyle","year":"2013","unstructured":"Coyle D, Coyle K, Cameron C, Lee K, Kelly S, Steiner S, et al. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Value Health. 2013;16(4):498\u2013506.","journal-title":"Value Health"},{"issue":"Supplement_1","key":"519_CR36","doi-asserted-by":"publisher","first-page":"euad122-024","DOI":"10.1093\/europace\/euad122.024","volume":"25","author":"E Karlsson","year":"2023","unstructured":"Karlsson E, Kiviniemi T, Halminen O, Lehtonen O, Haukka J, Mustonen P, et al. Temporal relation of disease onsets in patients with acute myocardial infarction and atrial fibrillation-results from a nationwide registry study. Europace. 2023;25(Supplement_1):euad122-024.","journal-title":"Europace"},{"issue":"1","key":"519_CR37","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1161\/STROKEAHA.123.044448","volume":"55","author":"J Putaala","year":"2024","unstructured":"Putaala J, Teppo K, Halminen O, Haukka J, Tiili P, Jaakkola J, et al. Ischemic stroke temporally associated with new-onset atrial fibrillation: a population-based registry-linkage study. Stroke. 2024;55(1):122\u201330.","journal-title":"Stroke"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-025-00519-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-025-00519-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-025-00519-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T01:17:07Z","timestamp":1763687827000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-025-00519-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["519"],"URL":"https:\/\/doi.org\/10.1007\/s40801-025-00519-5","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"type":"print","value":"2199-1154"},{"type":"electronic","value":"2198-9788"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"22 September 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K.E.J.A.: Grants: The Finnish Foundation for Cardiovascular Research; Speaker: Bayer, Pfizer, Boehringer-Ingelheim. Ja.H.: Research grants: EU Horizon 2020, EU FP7; Speaker: Bayer. J.P.: Grants: Academy of Finland, Finnish Foundation for Cardiovascular research, Sigrid Juselius Foundation, Helsinki and Uusimaa Hospital District; Consultant: Herantis Pharma, Novo Nordisk; Speaker: Abbott, BMS-Pfizer, Bayer. P.M.: Consultant: Roche, BMS-Pfizer-alliance, Novartis Finland, Boehringer Ingelheim, MSD Finland, Bayer. K.T.: Grants: The Finnish Foundation for Cardio vascular Research. A.L.A.: Grants: Finnish Foundation for Cardiovascular Research, Sigrid Juselius Foundation; Speaker: Abbott, Johnson & Johnson, Sanofi, Bayer, Boehringer-Ingelheim. Ju.H.: Grants: Finnish Foundation for Cardiovascular Research, EU Horizon 2020; Speaker: Novo Nordisk. M.Le.: Consultant and speaker: BMS-Pfizer-alliance, Bayer, Boehringer-Ingelheim, MSD; Grants: Boehringer-Ingelheim. M.Li.: Speaker: BMS-Pfizer alliance. All other authors declare they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Conceptualization: Olli Halminen, K.E. Juhani Airaksinen, Jari Haukka, Jukka Putaala, Pirjo Mustonen, Aapo L. Aro, Juha Hartikainen, Mika Lehto, Miika Linna. Data curation: Olli Halminen, Ossi Lehtonen, Jari Haukka, Miika Linna. Formal analysis: Ossi Lehtonen, Olli Halminen, Miika Linna. Funding acquisition: Mika Lehto. Methodology: Olli Halminen, Miika Linna. Visualization: Ossi Lehtonen, Olli Halminen. Writing\u2014original draft: Ossi Lehtonen. Writing\u2014review and editing: Olli Halminen, K.E. Juhani Airaksinen, Jari Haukka, Jukka Putaala, Pirjo Mustonen, Aapo L. Aro, Juha Hartikainen, Mika Lehto, Miika Linna, Konsta Teppo, Elis Kouki. All authors read and approved the final version.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}},{"value":"The ethical permission is permitted by the ethical committee of the Medical Faculty of Helsinki University, Helsinki Finland (nr. 15\/2017 and 15\/2024), and study permission was obtained from the Helsinki University Hospital (HUS\/46\/2018 and HUS\/217\/2024).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The study at hand only included previously collected registry information, and thus the patients were not contacted at any point. The data were pseudonymized, and the patients could therefore not be directly identified. Informed consent was waived because of the retrospective design of the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Code is available from the corresponding author on a reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The data underlying this article cannot be shared publicly due to its sensitive nature and in accordance with the agreements made with the Finnish registries. Requests to access the data set from qualified researchers trained in human subject confidentiality protocols may be sent to the Finnish national register holders (KELA, Finnish Institute for Health and Welfare, Population Register Centre, and Tax Register).","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}